WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Report of the Committee of Principal Investigators
- PMID: 6147641
WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Report of the Committee of Principal Investigators
Abstract
This is the final report on mortality amongst men in the WHO cooperative trial of the prevention of ischaemic heart disease (IHD) by clofibrate and it takes the follow-up a further 4 years to the end of 1982. Mean observation was 13.2 years, 5.3 in the trial and 7.9 afterwards. 1788 deaths were recorded in 208 000 man-years. In the 877 new deaths reported here, there was an excess of 9 deaths in the high cholesterol control group compared with the clofibrate-treated group. In the whole period there were 70 (11%) more deaths in the clofibrate-treated group. Excess mortality in the clofibrate-treated group was much greater during the "treatment period" (there was an excess of 47% during treatment compared with 5% after treatment had ended) and was due to a wide variety of causes other than IHD. Thus, the excess mortality in the clofibrate-treated group has not continued after the end of treatment. The substantial excess previously reported remains unexplained.
Similar articles
-
W.H.O. cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up. Report of the Committee of Principal Investigators.Lancet. 1980 Aug 23;2(8191):379-85. Lancet. 1980. PMID: 6105515 Clinical Trial.
-
Ischaemic heart disease: a secondary prevention trial using clofibrate. Report by a research committee of the Scottish Society of Physicians.Br Med J. 1971 Dec 25;4(5790):775-84. Br Med J. 1971. PMID: 4943606 Free PMC article. Clinical Trial.
-
A cooperative trial on the primary prevention of ischaemic heart disease using clofibrate: design, methods, and progress.Bull World Health Organ. 1973;48(2):243-56. Bull World Health Organ. 1973. PMID: 4578364 Free PMC article. Clinical Trial.
-
[Trials of primary prevention by diet or hypolipidemic treatment].Arch Mal Coeur Vaiss. 1992 Sep;85 Spec No 2:97-103. Arch Mal Coeur Vaiss. 1992. PMID: 1285703 Review. French.
-
Lipid lowering effects on cardiovascular morbidity and mortality. Clinical evidence and therapeutic guidelines.Arq Bras Cardiol. 1988 Jul;51(1):43-8. Arq Bras Cardiol. 1988. PMID: 3073735 Review. No abstract available.
Cited by
-
Dyslipidemia in patients with nonalcoholic fatty liver disease.Semin Liver Dis. 2012 Feb;32(1):22-9. doi: 10.1055/s-0032-1306423. Epub 2012 Mar 13. Semin Liver Dis. 2012. PMID: 22418885 Free PMC article. Review.
-
Peroxisome proliferator-activated receptor-alpha and liver cancer: where do we stand?J Mol Med (Berl). 2005 Oct;83(10):774-85. doi: 10.1007/s00109-005-0678-9. Epub 2005 Jun 23. J Mol Med (Berl). 2005. PMID: 15976920 Review.
-
The clofibrate saga: a retrospective commentary.Br J Clin Pharmacol. 2012 Dec;74(6):907-10. doi: 10.1111/j.1365-2125.2012.04282.x. Br J Clin Pharmacol. 2012. PMID: 22486628 Free PMC article. No abstract available.
-
Mechanistic considerations for human relevance of cancer hazard of di(2-ethylhexyl) phthalate.Mutat Res. 2012 Apr-Jun;750(2):141-158. doi: 10.1016/j.mrrev.2011.12.004. Epub 2011 Dec 20. Mutat Res. 2012. PMID: 22198209 Free PMC article. Review.
-
Cholesterol reduction and coronary artery disease. An overview of clinical trials up to 1986.Drugs. 1988;36 Suppl 3:27-31. doi: 10.2165/00003495-198800363-00008. Drugs. 1988. PMID: 3076117 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
